BR112014010406A2 - cromatografia de sobrecarga e eluto - Google Patents

cromatografia de sobrecarga e eluto

Info

Publication number
BR112014010406A2
BR112014010406A2 BR112014010406A BR112014010406A BR112014010406A2 BR 112014010406 A2 BR112014010406 A2 BR 112014010406A2 BR 112014010406 A BR112014010406 A BR 112014010406A BR 112014010406 A BR112014010406 A BR 112014010406A BR 112014010406 A2 BR112014010406 A2 BR 112014010406A2
Authority
BR
Brazil
Prior art keywords
overload
elute chromatography
chromatography
elute
polypeptide
Prior art date
Application number
BR112014010406A
Other languages
English (en)
Portuguese (pt)
Inventor
Mehta Amit
Nadarajah Deepa
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014010406(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112014010406A2 publication Critical patent/BR112014010406A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/14—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the introduction of the feed to the apparatus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112014010406A 2011-11-02 2012-11-02 cromatografia de sobrecarga e eluto BR112014010406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554898P 2011-11-02 2011-11-02
PCT/US2012/063242 WO2013067301A1 (en) 2011-11-02 2012-11-02 Overload and elute chromatography

Publications (1)

Publication Number Publication Date
BR112014010406A2 true BR112014010406A2 (pt) 2017-04-25

Family

ID=48192803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010406A BR112014010406A2 (pt) 2011-11-02 2012-11-02 cromatografia de sobrecarga e eluto

Country Status (25)

Country Link
US (3) US20140301977A1 (https=)
EP (3) EP2773438B2 (https=)
JP (4) JP6356607B2 (https=)
KR (1) KR20140091721A (https=)
CN (2) CN107163101B (https=)
AU (1) AU2012323995B2 (https=)
BR (1) BR112014010406A2 (https=)
CA (1) CA2854330A1 (https=)
DK (2) DK3257564T4 (https=)
ES (3) ES3062963T3 (https=)
FI (1) FI3257564T4 (https=)
HR (2) HRP20260140T1 (https=)
HU (2) HUE035685T2 (https=)
IL (1) IL232146A0 (https=)
LT (1) LT3257564T (https=)
MX (1) MX2014005330A (https=)
PL (3) PL3257564T5 (https=)
PT (1) PT3257564T (https=)
RS (1) RS58472B2 (https=)
RU (1) RU2014121884A (https=)
SG (1) SG11201402019TA (https=)
SI (2) SI3257564T2 (https=)
TR (1) TR201903707T4 (https=)
WO (1) WO2013067301A1 (https=)
ZA (1) ZA201402932B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101619865B1 (ko) 2010-07-30 2016-05-11 이엠디 밀리포어 코포레이션 크로마토그래피 매질
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
HUE035685T2 (en) 2011-11-02 2018-05-28 Hoffmann La Roche Overload and elute chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014066471A1 (en) 2012-10-24 2014-05-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP6326499B2 (ja) 2013-12-12 2018-05-16 イー・エム・デイー・ミリポア・コーポレイシヨン アクリルアミド含有フィルターを使用したタンパク質分離
EP3079722B1 (en) * 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Method for thioether conjugation of proteins
KR20150083689A (ko) * 2014-01-10 2015-07-20 삼성전자주식회사 항 c-Met 항체 정제 방법
PL3116891T3 (pl) 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
CN106460027B (zh) * 2014-03-24 2020-07-31 日东纺绩株式会社 使用阳离子性接枝聚合物的目标物分离浓缩方法
US10280195B2 (en) * 2014-05-28 2019-05-07 Agency For Science, Technology And Research Virus reduction method
RU2017101727A (ru) * 2014-06-25 2018-07-25 ДжейЭйчЭл БИОТЕК, ИНК. Способы и реагенты для очистки белков
CN104208719B (zh) * 2014-09-24 2017-05-03 北京天广实生物技术股份有限公司 一种抗体偶联药物的阳离子交换层析纯化方法
EP3230299A1 (en) 2014-12-08 2017-10-18 EMD Millipore Corporation Mixed bed ion exchange adsorber
HRP20192217T1 (hr) * 2015-03-06 2020-02-21 F. Hoffmann - La Roche Ag ULTRA-PROČIŠĆENI DsbA I DsbC TE POSTUPCI NJIHOVE IZRADE I UPORABE
CN106290591B (zh) * 2015-05-14 2019-07-26 上海医药工业研究院 一种庆大霉素C1a的检测方法
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
SI3337812T1 (sl) 2015-08-21 2021-08-31 F. Hoffmann-La Roche Ag Postopek za zmanjševanje beljakovin gostiteljske celice v afinitetni kromatografiji
EP3337818B1 (en) * 2015-08-21 2026-03-18 F. Hoffmann-La Roche AG Affinity chromatography purification with low conductivity wash buffer
HRP20250718T1 (hr) * 2016-08-15 2025-08-15 F. Hoffmann-La Roche Ag Kromatografski postupak za kvantifikaciju neionskog surfaktanta u sastavu koji sadrži neionski surfaktant i polipeptid
GB201702856D0 (en) * 2017-02-22 2017-04-05 Ge Healthcare Bio Sciences Ab Method in continuous chromatography
US11339377B2 (en) * 2017-11-08 2022-05-24 Bluesky Immunotherapies Gmbh SO3 chromatography for use in a method for virus purification
US11999975B2 (en) * 2018-07-04 2024-06-04 Probiogen Ag Method for purifying an enveloped virus
US12306152B2 (en) * 2018-12-21 2025-05-20 Solventum Intellectual Properties Company Method for testing a chromatography device used for ion exchange
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
CN111351876A (zh) * 2020-04-01 2020-06-30 上海中科新生命生物科技有限公司 一种抗体药中宿主细胞蛋白半绝对定量检测方法
US11379651B1 (en) * 2020-07-06 2022-07-05 Turtl Surf & Immerse Limited Methods and systems for interactive content creation
EP4217383A1 (en) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
JP7620456B2 (ja) * 2021-03-15 2025-01-23 株式会社カネカ κ鎖を含む抗体の製造方法
EP4408856A4 (en) * 2021-09-28 2025-11-12 Kashiv Biosciences Llc IMPROVED PROCESS FOR PROTEIN PURIFICATION
EP4423109A4 (en) * 2021-10-27 2025-12-24 Plasma Tech Llc COMPOSITIONS AND METHODS FOR ISOLATING PROTEINS

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
CA2106612C (en) * 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
MX340738B (es) * 1996-09-13 2016-07-22 Shire Human Genetic Therapies Terapia para deficiencia de a-galactosidasa a.
DE69738075T2 (de) * 1996-11-27 2008-05-21 Genentech, Inc., South San Francisco Affinitätsreinigung von polypeptiden an einer protein a-matrix
NZ507557A (en) * 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US8372954B2 (en) 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
DK1355936T3 (da) * 2001-02-01 2007-10-29 Biogen Idec Inc Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20070261962A1 (en) * 2002-04-02 2007-11-15 Ryszard Gajek Separation Systems with Charge Mosaic Membrane
AU2003301399B2 (en) * 2002-10-18 2006-07-06 Asahi Kasei Medical Co., Ltd. Microporous hydrophilic membrane
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
EP1869065B1 (en) 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
WO2006116064A2 (en) 2005-04-22 2006-11-02 Waters Investments Limited Apparatus and methods for mass-spectrometric directed purification of biopolymers
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
BRPI0716382B8 (pt) * 2006-08-28 2021-05-25 Ares Trading Sa método para reduzir o teor de porções de fc livres em um fluido compreendendo uma proteína contendo fc, e uso de cromatografia de troca catiônica
CN101679509A (zh) 2007-06-01 2010-03-24 弗·哈夫曼-拉罗切有限公司 免疫球蛋白纯化
DE102009005479A1 (de) * 2009-01-21 2010-07-22 Sartorius Stedim Biotech Gmbh Vorrichtung und Verfahren für die Stofftrennung
JP5614936B2 (ja) * 2009-02-19 2014-10-29 旭化成ケミカルズ株式会社 アニオン交換基が固定された多孔膜を用いた核酸の精製方法
EP2462157B1 (en) * 2009-08-07 2020-06-17 EMD Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
WO2011035282A1 (en) 2009-09-21 2011-03-24 Ge Healthcare Bio-Sciences Ab Dual capture separation
CN102094034A (zh) * 2009-12-09 2011-06-15 泰州新生源生物医药有限公司 一种重组人Fc融合长效干扰素的纯化工艺
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012068134A1 (en) * 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
HUE035685T2 (en) 2011-11-02 2018-05-28 Hoffmann La Roche Overload and elute chromatography

Also Published As

Publication number Publication date
PT3257564T (pt) 2019-03-22
WO2013067301A1 (en) 2013-05-10
LT3257564T (lt) 2019-04-10
HRP20190485T1 (hr) 2019-04-19
ZA201402932B (en) 2016-08-31
RS58472B1 (sr) 2019-04-30
ES2637423T3 (es) 2017-10-13
JP7203928B2 (ja) 2023-01-13
PL3257564T5 (pl) 2024-10-07
AU2012323995A1 (en) 2013-05-16
RU2014121884A (ru) 2015-12-10
US20190023768A1 (en) 2019-01-24
SI3257564T1 (sl) 2019-04-30
EP2773438B1 (en) 2017-06-14
JP2022033774A (ja) 2022-03-02
EP3257564A1 (en) 2017-12-20
SI3257564T2 (sl) 2024-10-30
ES3062963T3 (en) 2026-04-14
EP2773438A1 (en) 2014-09-10
CA2854330A1 (en) 2013-05-10
HRP20190485T4 (hr) 2024-09-27
ES2637423T5 (es) 2022-03-17
JP6356607B2 (ja) 2018-07-11
JP6979442B2 (ja) 2021-12-15
CN107163101A (zh) 2017-09-15
US20140301977A1 (en) 2014-10-09
EP3527274C0 (en) 2025-12-24
KR20140091721A (ko) 2014-07-22
SI2773438T1 (sl) 2017-10-30
AU2012323995B2 (en) 2016-06-09
SG11201402019TA (en) 2014-09-26
DK3257564T3 (en) 2019-04-15
JP2014532718A (ja) 2014-12-08
HK1201489A1 (zh) 2015-09-04
EP2773438A4 (en) 2015-06-03
EP2773438B2 (en) 2021-10-20
EP3527274B1 (en) 2025-12-24
RS58472B2 (sr) 2024-10-31
DK3257564T4 (da) 2024-09-02
ES2717536T5 (en) 2025-02-04
HUE035685T2 (en) 2018-05-28
PL3257564T3 (pl) 2019-06-28
IL232146A0 (en) 2014-05-28
NZ624317A (en) 2016-06-24
FI3257564T4 (fi) 2024-08-30
EP3257564B1 (en) 2019-01-23
HUE043755T2 (hu) 2019-09-30
PL2773438T3 (pl) 2017-11-30
MX2014005330A (es) 2014-09-08
JP2020059718A (ja) 2020-04-16
PL3527274T3 (pl) 2026-04-07
EP3257564B2 (en) 2024-05-29
DK2773438T3 (en) 2017-08-21
JP2018184405A (ja) 2018-11-22
HRP20260140T1 (hr) 2026-03-27
EP3527274A1 (en) 2019-08-21
CN104023804B (zh) 2017-05-24
ES2717536T3 (es) 2019-06-21
DK2773438T4 (da) 2022-01-03
CN107163101B (zh) 2021-08-17
TR201903707T4 (tr) 2019-04-22
PL2773438T5 (pl) 2022-01-17
SI2773438T2 (sl) 2022-05-31
US20210206836A1 (en) 2021-07-08
CN104023804A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
BR112014010406A2 (pt) cromatografia de sobrecarga e eluto
BR112015001618A2 (pt) composições fungicidas
MX344248B (es) Metodos de purificacion de polipeptidos.
BR112014016287A2 (pt) composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma
MX373763B (es) Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica.
CL2013003790A1 (es) Composicion de aglutinante para la aglomeracion de minerales finas y procedimiento de granulacion utilizando el mismo
AR087715A1 (es) Anticuerpos anti pcsk9 y usos de los mismos
TN2014000079A1 (en) Selective and reversible inhibitors of ubiquitin specific protease 7
EP2931971A4 (en) WET PAD MATERIAL MICROFIBRILLED MATERIAL COMPOSITION
EP2690173A4 (en) PROTEIN FOR AN AFFINITY SEPARATION MATRIX
MX2013003182A (es) Purificacion de anticuerpos por cromatografia de lecho movil simulada.
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
MX2015012812A (es) Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.
BR112014002884A2 (pt) composição para estimulação ovariana controlada
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
IL226296A0 (en) Enrichment and concentration of isoforms of @מוזר@נבחר@במיטרות@chromatographic washing and overloading
IN2013CN09704A (https=)
BR112014009376A2 (pt) composições
BR112013022052A2 (pt) ligantes antagonísticos de dr3
BR112014004403A2 (pt) compostos fotorreativos
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
BR112014001950A2 (pt) métodos e composições para controlar pragas de nemátodos
PH12014501891A1 (en) Substituted chroman compounds as calcium sensing receptor modulators
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]